Acadia Pharmaceuticals (ACAD) Other Non-Current Assets (2010 - 2026)

Acadia Pharmaceuticals' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets fell 55.21% year-over-year to $3.9 million in Q1 2026; TTM through Mar 2026 was $3.9 million, a 55.21% decrease from a year earlier, with the FY2025 full-year figure at $7.8 million, down 10.55% from the prior year.
• Other Non-Current Assets retreated to $3.9 million in Q1 2026 per ACAD's latest filing, from $7.8 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $8.8 million in Q3 2024 and bottomed at $2.3 million in Q2 2025.
• The 5-year median for Other Non-Current Assets is $5.8 million (2022), against an average of $6.1 million.
• Across the five-year window, Other Non-Current Assets surged 86.13% in 2022 and slumped 65.86% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $5.8 million in 2022, then changed by 0.0% to $5.8 million in 2023, then surged by 51.99% to $8.8 million in 2024, then fell by 10.55% to $7.8 million in 2025, then sank by 49.93% to $3.9 million in 2026.
• Per Business Quant, the three latest ACAD Other Non-Current Assets figures stand at $3.9 million (Q1 2026), $7.8 million (Q4 2025), and $3.0 million (Q3 2025).